Skip to main content
. 2023 Jan 26;13:1061502. doi: 10.3389/fonc.2023.1061502

Figure 1.

Figure 1

Distribution of percent change in normalized rCBV (nRCBV) and standardized rCBV (sRCBV) from baseline to week 2 (A), week 8 (B), and week 16 (C) for 2D-T1 non-progressors by overall survival status at 1 year (OS-1) and progression-free survival status at 6 months (PFS-6).